[Kim Saemi, Edaily Reporter] GC Biopharma Corp. has secured its largest-ever flu vaccine order in Thailand, the company announced April 23, with plans to supply 5.94 million doses of its ‘GCFLU’ vaccine to Thailand. The bidding volume is estimated to be around 20 billion won.
 | | GC Biopharma Corp. Headquarters (Source=GC Biopharma Corp.) |
|
The order includes contracts from Thailand’s Government Pharmaceutical Organization (GPO), the Department of Disease Control (DDC), and the private market. With this deal, GCFLU is expected to surpass a cumulative total of 15 million doses supplied to Thailand since entering the market in 2014.
Thailand follows flu vaccination guidelines from the World Health Organization (WHO) for both regions. The country has year-round demand for flu vaccines.
GC Biopharma won tenders from both the GPO’s Northern and Southern Hemisphere bids, as well as the Thai government’s national procurement involving the DDC. The volume of flu vaccines supplied to Thailand’s private sector also grew 112% compared to the previous year.
GCFLU is currently exported to 63 countries, with volumes and global reach continuing to expand annually. The vaccine has established itself as a key player in the global flu vaccine market. GC Biopharma is also the largest supplier of flu vaccines to WHO-affiliated international organizations, with cumulative production exceeding 300 million doses.
Woojin Lee, head of global business at GC Biopharma, credited strong regulatory support from South Korea’s Ministry of Food and Drug Safety for accelerating export approvals and batch release timelines. “With our product quality proven through years of international procurement contracts, we are committed to promoting the excellence of GCFLU globally,” he said.
